Blueprint Medicines Corp

NASDAQ:BPMC  
49.89
-0.62 (-1.23%)
Regulatory, Other Pre-Announcement

Blueprint Medicines Reports Progress In Systemic Mastocytosis Treatment

Published: 06/09/2022 11:21 GMT
Blueprint Medicines Corp (BPMC) - Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis.
Blueprint Medicines-new Analyses Showing Ayvakit Significantly Improved Overall Survival in Advanced Sm Versus Real-world Data for Prior Standard Therapies.
Blueprint Medicines - Primary Endpoint of Pioneer Trial of Ayvakit in Non-advanced Sm to Be Updated to Mean Change in Total Symptom Score.
Blueprint Medicines Corp - on Track to Report Top-line Registrational Data From Pioneer Trial in Late Summer 2022.
Blueprint Medicines -continues to Plan to Submit a Supplemental New Drug Application to FDA for Ayvakit for Non-advanced Sm by End of 2022.